

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Hygeia Healthcare Holdings Co., Limited**

**海吉亚医疗控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 6078)**

**CONTINUING CONNECTED TRANSACTIONS  
(1) REVISION OF ANNUAL CAP FOR THE EXISTING RENHE  
MEDICAL CONSUMABLES PROCUREMENT AGREEMENT;  
AND  
(2) THE NEW PROCUREMENT AGREEMENTS  
WITH HANDAN RENHE HOSPITAL**

References are made to the Announcements in relation to the existing continuing connected transactions contemplated under the Existing Procurement Agreements.

**(1) REVISION OF ANNUAL CAP FOR THE EXISTING RENHE  
MEDICAL CONSUMABLES PROCUREMENT AGREEMENT**

Based on the information currently available to the Board, the Board anticipates that the Original Annual Cap for the year ending December 31, 2023 under the Existing Renhe Medical Consumables Procurement Agreement will not be sufficient to meet the business needs. Accordingly, the Board proposed to revise and increase the Original Annual Cap from RMB6.9 million to RMB8.0 million for the year ending December 31, 2023 (i.e. the Revised Annual Cap).

**(2) THE NEW PROCUREMENT AGREEMENTS WITH HANDAN  
RENHE HOSPITAL**

As the terms of the Existing Procurement Agreements will expire on December 31, 2023, (i) Qihai Medicine, a wholly-owned subsidiary of the Company, and Handan Renhe Hospital has entered into the New Renhe Medicine Procurement Agreement on November 30, 2023, and (ii) Jiangsu Medical, a wholly-owned subsidiary of the Company, and Handan Renhe Hospital has entered into the New Renhe Medical Consumables Procurement Agreement on November 30, 2023. Pursuant to the New Procurement Agreements, each of Qihai Medicine and Jiangsu Medical agreed to supply, as required for the daily operation needs of Handan Renhe Hospital from time to time and within the scope of operation permit of Qihai Medicine and Jiangsu Medical, the Medicine and the Medical Consumables, to Handan Renhe Hospital in accordance with the terms and conditions therein.

## **LISTING RULES IMPLICATIONS**

As at the date of this announcement, Handan Renhe Hospital is a private not-for-profit hospital in which Xiangshang Investment (owned by Mr. Zhu and Ms. Zhu as to 40% and 60%, respectively) holds 30% organizer's interest (舉辦人權益) and hence an associate of Mr. Zhu and Ms. Zhu. Accordingly, Handan Renhe Hospital is a connected person of the Company under the Listing Rules and the transactions contemplated under the Existing Renhe Medical Consumables Procurement Agreement and the New Procurement Agreements constitute continuing connected transactions of the Company under Chapter 14A of the Listing Rules.

Pursuant to Rule 14A.54 of the Listing Rules, if the Company proposes to revise the annual caps for continuing connected transactions, the Company will have to re-comply with provisions of Chapter 14A of the Listing Rules applicable to the relevant continuing connected transaction.

Pursuant to Rule 14A.54(2) of the Listing Rules, if the Company proposes to renew continuing connected transactions, the Company will have to re-comply with provisions of Chapter 14A of the Listing Rules applicable to the relevant continuing connected transactions.

As the highest applicable percentage ratio calculated in respect of (i) the transactions contemplated under the Existing Renhe Medical Consumables Procurement Agreement as captured under the Revised Annual Cap and (ii) the transactions contemplated under each of the New Procurement Agreements exceed 0.1% but all of the applicable percentage ratios are less than 5%, the transactions contemplated thereunder are subject to the reporting, announcement and annual review requirements but are exempt from the independent shareholders' approval requirements under Chapter 14A of the Listing Rules.

References are made to the Announcements in relation to the existing continuing connected transactions contemplated under the Existing Procurement Agreements.

### **(1) REVISION OF ANNUAL CAP FOR THE EXISTING RENHE MEDICAL CONSUMABLES PROCUREMENT AGREEMENT**

#### **Revision of the Original Annual Cap**

Based on the information currently available to the Board, the Board anticipates that the Original Annual Cap for the year ending December 31, 2023 under the Existing Renhe Medical Consumables Procurement Agreement will not be sufficient to meet the business needs. Accordingly, the Board proposed to revise and increase the Original Annual Cap from RMB6.9 million to RMB8.0 million for the year ending December 31, 2023 (i.e. the Revised Annual Cap).

Save for the revision of the Original Annual Cap, all other terms and conditions (including the relevant pricing policy) of the Existing Renhe Medical Consumables Procurement Agreement remain unchanged. Details of the Existing Renhe Medical Consumables Procurement Agreement are set out in the Announcements.

As at the date of this announcement, the aggregate total transaction amount have not exceeded the Original Annual Cap for the year ending December 31, 2023.

### **Basis of the Revised Annual Cap**

The Revised Annual Cap was determined principally with reference to the factors set out in the Announcements, as well as taking into account: (i) the unaudited historical transaction amount of approximately RMB5.2 million for the ten months ended October 31, 2023 (representing approximately 75.4% of the Original Annual Cap for the year ending December 31, 2023); (ii) the expected increase in number of patient visits after the COVID-19 pandemic as the brand influence of Handan Renhe Hospital in the local area increased as a result of the implementation of upgrading and development plan of Handan Renhe Hospital; and (iii) the expected increase in demand for Medical Consumables by Handan Renhe Hospital in the fourth quarter of 2023.

Shareholders and potential investors should note that the Revised Annual Cap should not be construed as an assurance or forecast by the Company of the future revenue of the Group under the terms of the Existing Renhe Medical Consumables Procurement Agreement.

### **Historical Transaction Amounts**

The historical transaction amounts in relation to the procurement of Medical Consumables paid by Handan Renhe Hospital to the Group under the Existing Renhe Medical Consumables Procurement Agreement for each of the years ended December 31, 2021 and 2022 and the ten months ended October 31, 2023 was approximately RMB0.5 million, RMB5.2 million and RMB5.2 million, respectively.

## **(2) THE NEW PROCUREMENT AGREEMENTS WITH HANDAN RENHE HOSPITAL**

### **I. THE NEW RENHE MEDICINE PROCUREMENT AGREEMENT**

As the term of the Existing Renhe Medicine Procurement Agreement will expire on December 31, 2023, Qihai Medicine, a wholly-owned subsidiary of the Company, and Handan Renhe Hospital has entered into the New Renhe Medicine Procurement Agreement on November 30, 2023. The terms of the New Renhe Medicine Procurement Agreement are substantially the same as those of the Existing Renhe Medicine Procurement Agreement.

The principal terms of the New Renhe Medicine Procurement Agreement are set out below:

**Date:** November 30, 2023

**Parties:** (1) Qihai Medicine  
(2) Handan Renhe Hospital

**Term:** From January 1, 2024 to December 31, 2026

**Subject Matter:** Pursuant to the New Renhe Medicine Procurement Agreement, Qihai Medicine agreed to supply to Handan Renhe Hospital, as required for the daily operation needs of Handan Renhe Hospital, from time to time and within the scope of operation permit of Qihai Medicine, the Medicine (including, but not limited to, the medicine for the treatment of breast cancer, ovarian cancer, gastric cancer, lung cancer, uremia and mental illness (such as Trastuzumab for Injection, Paclitaxel Injection, Recombinant Human Erythropoietin Injection (CHO Cell) and Olanzapine Tablets)).

**Pricing Policy:** The purchase prices for the Medicine shall be on normal commercial terms and determined after arm's length negotiations between the parties. The prices for the Medicine to be supplied by the Group under the New Renhe Medicine Procurement Agreement are subject to the rules and regulations promulgated by the national or local pricing authority(ies) and determined with reference to the government-prescribed prices set out in the Catalogues.

For the Medicine not covered in the Catalogues, the prices shall be determined based on normal commercial terms after arm's length negotiation between the parties taking into account: (i) the nature and specification of the Medicine; (ii) the market supply and demand situation; (iii) the procurement costs of the Medicine; (iv) the volume of the purchase order; (v) the market share of Qihai Medicine; (vi) the comparative prices offered by independent third parties to the other hospitals within the same region if such comparative prices are made public; and (vii) any other factors affecting prices of the Medicine.

Such prices shall be no more favorable than the prices of the same Medicines offered by the Group to the other hospitals within the same region. Handan Renhe Hospital is not obliged to purchase the Medicine from the Group if the prices offered by the Group differ significantly from the prevailing government-prescribed prices in the Catalogues or market prices, as the case may be.

**Payment Terms:** Handan Renhe Hospital shall settle the payment within 90 days following the date of receipt of the Medicine purchased. The payment for the Medicine will be settled by bank transfers or other payment methods as agreed by the parties.

### **Historical Transaction Amounts**

The historical transaction amounts in relation to the procurement of Medicine paid by Handan Renhe Hospital to the Group under the Existing Renhe Medicine Procurement Agreement for each of the years ended December 31, 2021 and 2022 and the ten months ended October 31, 2023 was approximately nil<sup>1</sup>, RMB4.5 million and RMB3.2 million, respectively.

### **Proposed Annual Caps for the Three Years Ending December 31, 2026**

The annual caps for the transactions contemplated under the New Renhe Medicine Procurement Agreement for the three years ending December 31, 2026 are expected to be as follows:

**Proposed annual caps for  
the years ending December 31,  
2024                  2025                  2026**  
*(RMB in million)*

Amounts to be paid by Handan Renhe Hospital to Qihai Medicine in respect of the procurement of the Medicine	10.0	15.0	20.0
---	------	------	------

<sup>1</sup> Qihai Medicine was established on August 11, 2021 and officially commenced operations by the end of 2021. As such, there were no transactions conducted under the Existing Renhe Medicine Procurement Agreement for the year ended December 31, 2021.

The above annual caps under the New Renhe Medicine Procurement Agreement were determined principally with reference to: (i) the historical transaction amounts in respect of the procurement of Medicine by Handan Renhe Hospital in 2021, 2022 and the first ten months of 2023; (ii) the anticipated increase in demand for Medicine by Handan Renhe Hospital in light of the increase in number of patient visits after the COVID-19 pandemic as the brand influence of Handan Renhe Hospital in the local area increased; (iii) the prevailing market prices of the Medicine; and (iv) a buffer in preparation of the potential price fluctuations.

## **II. THE NEW RENHE MEDICAL CONSUMABLES PROCUREMENT AGREEMENT**

As the term of the Existing Renhe Medical Consumables Procurement Agreement will expire on December 31, 2023, Jiangsu Medical, a wholly-owned subsidiary of the Company, and Handan Renhe Hospital has entered into the New Renhe Medical Consumables Procurement Agreement on November 30, 2023. The terms of the New Renhe Medical Consumables Procurement Agreement are substantially the same as those of the Existing Renhe Medical Consumables Procurement Agreement.

The principal terms of the New Renhe Medical Consumables Procurement Agreement are set out below:

- Date:** November 30, 2023
- Parties:**
- (1) Jiangsu Medical
  - (2) Handan Renhe Hospital
- Term:** From January 1, 2024 to December 31, 2026
- Subject Matter:** Pursuant to the New Renhe Medical Consumables Procurement Agreement, Jiangsu Medical agreed to supply to Handan Renhe Hospital, as required for the daily operation needs of Handan Renhe Hospital, from time to time and within the scope of operation permit of Jiangsu Medical, the Medical Consumables (including, but not limited to, general consumables (for example, medical gauze, syringes and cotton swabs) and high value medical consumables (for example, dialyzers and hemoperfusion devices)).

**Pricing Policy:**

The purchase prices for the Medical Consumables shall be on normal commercial terms and determined after arm's length negotiations between the parties. The prices for the Medical Consumables to be supplied by the Group under the New Renhe Medical Consumables Procurement Agreement are subject to the rules and regulations promulgated by the national or local pricing authority(ies) and determined with reference to the government-prescribed prices set out in the Catalogues.

For the Medical Consumables not covered in the Catalogues, the prices shall be determined based on normal commercial terms after arm's length negotiation between the parties taking into account: (i) the nature and specification of the Medical Consumables; (ii) the market supply and demand situation; (iii) the procurement costs of the Medical Consumables; (iv) the volume of the purchase order; (v) the market share of Jiangsu Medical; (vi) the comparative prices offered by independent third parties to the other hospitals within the same region if such comparative prices are made public; and (vii) any other factors affecting prices of the Medical Consumables.

Such prices shall be no more favorable than the prices of the same Medical Consumables offered by the Group to the other hospitals within the same region. Handan Renhe Hospital is not obliged to purchase the Medical Consumables from the Group if the prices offered by the Group differ significantly from the prevailing government-prescribed prices in the Catalogues or market prices, as the case may be.

**Payment Terms:**

Jiangsu Medical shall deliver and transport the Medical Consumables within 10 business days following the date of receipt of the payment made by Handan Renhe Hospital for the Medical Consumables purchased. The payment for the Medical Consumables will be settled by bank transfers or other payment methods as agreed by the parties.

## Historical Transaction Amounts

Please refer to the section headed “(1) Revision of Annual Cap For The Existing Renhe Medical Consumables Procurement Agreement — Historical Transaction Amounts” in this announcement above for details of the historical transaction amounts in relation to the procurement of the Medical Consumables by Handan Renhe Hospital to the Group under the Existing Renhe Medical Consumables Procurement Agreement.

## Proposed Annual Caps for the Three Years Ending December 31, 2026

The annual caps for the transactions contemplated under the New Renhe Medical Consumables Procurement Agreement for the three years ending December 31, 2026 are expected to be as follows:

**Proposed annual caps for  
the years ending December 31,  
2024            2025            2026**  
*(RMB in million)*

Amounts to be paid by Handan Renhe Hospital to Jiangsu Medical in respect of the procurement of the Medical Consumables	11.3	16.5	22.5
---	------	------	------

The above annual caps under the New Renhe Medical Consumables Procurement Agreement were determined principally with reference to: (i) the historical transaction amounts in respect of the procurement of Medical Consumables by Handan Renhe Hospital in 2021, 2022 and the first ten months of 2023; (ii) the anticipated increase in demand for Medical Consumables by Handan Renhe Hospital in light of the increase in number of patient visits after the COVID-19 pandemic as the brand influence of Handan Renhe Hospital in the local area increased; (iii) the prevailing market prices of the Medical Consumables; and (iv) a buffer in preparation of the potential price fluctuations.



## **REASONS FOR AND BENEFITS OF THE REVISED ANNUAL CAP UNDER THE EXISTING RENHE MEDICAL CONSUMABLES PROCUREMENT AGREEMENT AND THE ENTERING INTO OF THE NEW PROCUREMENT AGREEMENTS**

Qihai Medicine and Jiangsu Medical, both being wholly-owned subsidiaries of the Company, are principally engaged in the wholesale of medicine and medical consumables. The sales of Medicine and Medical Consumables to Handan Renhe Hospital are expected to be of a recurrent nature and will occur on a regular and continuing basis in the ordinary and usual course of businesses of the Group and Handan Renhe Hospital.

The Board has been carefully monitoring the historical transaction amounts of the transactions contemplated under the Existing Renhe Medical Consumables Procurement Agreement. Since the relaxing of the COVID-19 pandemic restrictions earlier this year, Handan Renhe Hospital has experienced a rapid increase in the number of patients and the Original Annual Cap proposed in the Announcements will no longer be sufficient to satisfy the increased demands. Taking into account the various basis set out above in this announcement and in view of the historical transaction amounts, the Board envisages that the aggregate value of the transactions contemplated under the Existing Renhe Medical Consumables Procurement Agreement would exceed the Original Annual Cap for the year ending December 31, 2023.

Further, the Directors are of the view that the entering of the New Procurement Agreements between Qihai Medicine and Jiangsu Medical, on the one hand, and Handan Renhe Hospital, on the other hand, are commercially beneficial to the Group and its in-network hospital as the entering of the New Procurement Agreements helps keep the centralization of procurement and provides a stable supply of Medicine and Medical Consumables to Handan Renhe Hospital, which promotes operational efficiency and enhances service level provided by the Group to the in-network hospitals as compared to purchasing from other external third-party suppliers. The entering of the New Procurement Agreements will also continue to improve the service quality of in-network hospitals, and satisfy the increasing demands of patients.

The Directors (including the independent non-executive Directors) consider that the transactions contemplated under the Existing Renhe Medical Consumables Procurement Agreement and the New Procurement Agreements are on normal commercial terms and the terms of the Existing Renhe Medical Consumables Procurement Agreement and the New Procurement Agreements and their respective new annual caps are fair and reasonable and in the interests of the Company and the Shareholders as a whole.

Mr. Zhu and Mr. Ren Ai (the husband of Ms. Zhu) are considered to have a material interest in the transactions contemplated under the Existing Renhe Medical Consumables Procurement Agreement and the New Procurement Agreements and have abstained from voting on the relevant resolutions. None of the other Directors has any material interest in the transactions contemplated under the Existing Renhe Medical Consumables Procurement Agreement and the New Procurement Agreements.

## **INTERNAL CONTROL MEASURES**

In order to continue to effectively implement the Existing Procurement Agreements and the New Procurement Agreements, the Company has adopted the following internal control measures:

- (a) the financial department and other relevant departments of the Company will continuously inspect and regularly collect and evaluate the pricing policies, transaction terms and actual transaction amounts under the Existing Procurement Agreements and the New Procurement Agreements to ensure that the transactions thereunder are conducted on normal commercial terms or on terms no more favorable than those available to independent third parties, and that the total transaction value of procurement of the Medicine and Medical Consumables will not exceed the relevant annual cap before the relevant approval procedures; and
- (b) the Company's auditors and the independent non-executive Directors will conduct annual review on the pricing policies, transaction terms and the annual caps under the Existing Procurement Agreements and the New Procurement Agreements.

## **INFORMATION OF THE PARTIES**

### **The Company**

The Company was incorporated in Cayman Islands as an exempted company with limited liability on September 12, 2018, the shares of which are listed on the Stock Exchange. The Group is principally engaged in the provision of healthcare services in the PRC. As an oncology-focused healthcare group, the Group endeavors to make healthcare services more accessible and affordable (讓醫療更溫暖), addressing unmet demand of oncology patients in China.

### **Qihai Medicine**

Qihai Medicine is a limited liability company established in the PRC on August 11, 2021 and a wholly-owned subsidiary of the Company. Qihai Medicine is principally engaged in the wholesale of medicine.

## **Jiangsu Medical**

Jiangsu Medical is a limited liability company established in the PRC on November 21, 2017 and a wholly-owned subsidiary of the Company. Jiangsu Medical is principally engaged in the wholesale of medical consumables.

## **Handan Renhe Hospital**

Handan Renhe Hospital is a private not-for-profit hospital established under the laws of the PRC and managed by the Group. It is held by Xiangshang Investment (owned by Mr. Zhu and Ms. Zhu as to 40% and 60%, respectively) as to 30% organizer's interest (舉辦人權益), which is regarded as an associate of Mr. Zhu and Ms. Zhu, and hence a connected person of the Company under the Listing Rules.

## **LISTING RULES IMPLICATIONS**

As at the date of this announcement, Handan Renhe Hospital is a private not-for-profit hospital in which Xiangshang Investment (owned by Mr. Zhu and Ms. Zhu as to 40% and 60%, respectively) holds 30% organizer's interest (舉辦人權益) and hence an associate of Mr. Zhu and Ms. Zhu. Accordingly, Handan Renhe Hospital is a connected person of the Company under the Listing Rules and the transactions contemplated under the Existing Renhe Medical Consumables Procurement Agreement and the New Procurement Agreements constitute continuing connected transactions of the Company under Chapter 14A of the Listing Rules.

Pursuant to Rule 14A.54 of the Listing Rules, if the Company proposes to revise the annual caps for continuing connected transactions, the Company will have to re-comply with provisions of Chapter 14A of the Listing Rules applicable to the relevant continuing connected transaction.

Pursuant to Rule 14A.54(2) of the Listing Rules, if the Company proposes to renew continuing connected transactions, the Company will have to re-comply with provisions of Chapter 14A of the Listing Rules applicable to the relevant continuing connected transactions.

As the highest applicable percentage ratio calculated in respect of (i) the transactions contemplated under the Existing Renhe Medical Consumables Procurement Agreement as captured under the Revised Annual Cap and (ii) the transactions contemplated under each of the New Procurement Agreements exceed 0.1% but all of the applicable percentage ratios are less than 5%, the transactions contemplated thereunder are subject to the reporting, announcement and annual review requirements but are exempt from the independent shareholders' approval requirements under Chapter 14A of the Listing Rules.

## DEFINITIONS

In this announcement, the following expressions have the meanings set out below unless the context otherwise requires:

“Announcements”	announcements of the Company dated September 14, 2021 and September 28, 2021 in relation to, among others, the entering into of the Existing Procurement Agreements
“associate”	has the meaning ascribed to it under the Listing Rules
“Board”	the board of Directors of the Company
“Catalogues”	the relevant Medicine Catalogue for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance (基本醫療保險、工傷保險和生育保險藥品目錄) and Medical Consumables Catalogue for Basic Medical Insurance (基本醫療保險醫用耗材目錄)
“China” or “PRC”	the People’s Republic of China, but for the purpose of this announcement and for geographical reference only, references herein to “China” and the “PRC” do not apply to Hong Kong, Macau and Taiwan
“Company”	Hygeia Healthcare Holdings Co., Limited (海吉亞醫療控股有限公司), an exempted company with limited liability incorporated under the laws of Cayman Islands on September 12, 2018, the Shares of which are listed on the Main Board of the Stock Exchange
“connected person(s)”	has the meaning ascribed to it under the Listing Rules
“Controlling Shareholder(s)”	has the meaning ascribed to it under the Listing Rules
“Director(s)”	director(s) of the Company
“Existing Procurement Agreements”	collectively, the Existing Renhe Medicine Procurement Agreement and the Existing Renhe Medical Consumables Procurement Agreement

“Existing Renhe Medical Consumables Procurement Agreement”	the Medical Consumables Procurement Framework Agreement (醫療耗材採購框架協議) entered into by Jiangsu Medical and Handan Renhe Hospital on September 14, 2021, details of which are set out in the Announcements
“Existing Renhe Medicine Procurement Agreement”	the Medicine Procurement Framework Agreement (藥品採購框架協議) entered into by Qihai Medicine and Handan Renhe Hospital on September 14, 2021, details of which are set out in the Announcements
“Group”	the Company together with its subsidiaries
“Handan Renhe Hospital”	Handan Renhe Hospital* (邯鄲仁和醫院), a private not-for-profit hospital established under the laws of the PRC which the Group acquired on July 31, 2011
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“Jiangsu Medical”	Jiangsu Hygeia Medical Equipment Co., Ltd.* (江蘇海吉亞醫療器材有限公司) (formerly known as Jiangsu Hygeia Supply Chain Management Co., Ltd.* (江蘇海吉亞供應鏈管理有限公司)), a limited liability company established in the PRC on November 21, 2017, and a wholly-owned subsidiary of the Company
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange, as amended or supplemented from time to time
“Medical Consumables”	the medical consumables to be supplied by Jiangsu Medical to Handan Renhe Hospital as required for the daily operation needs of Handan Renhe Hospital from time to time and within the scope of operation permit of Jiangsu Medical, includes but are not limited to, general consumables (for example, medical gauze, syringes and cotton swabs) and high value medical consumables (for example, dialyzers and hemoperfusion devices)

“Medicine”	the medicine to be supplied by Qihai Medicine to Handan Renhe Hospital as required for the daily operation needs of Handan Renhe Hospital from time to time and within the scope of operation permit of Qihai Medicine, includes but are not limited to, the medicine for the treatment of breast cancer, ovarian cancer, gastric cancer, lung cancer, uremia and mental illness (such as Trastuzumab for Injection, Paclitaxel Injection, Recombinant Human Erythropoietin Injection (CHO Cell) and Olanzapine Tablets)
“Mr. Zhu”	Mr. Zhu Yiwen (朱義文), father of Ms. Zhu, the founder of the Group, chairman of the Board, executive Director and one of the Controlling Shareholders
“Ms. Zhu”	Ms. Zhu Jianqiao (朱劍喬), daughter of Mr. Zhu and one of the Controlling Shareholders
“New Procurement Agreements”	collectively, the New Renhe Medicine Procurement Agreement and the New Renhe Medical Consumables Procurement Agreement
“New Renhe Medical Consumables Procurement Agreement”	the new Medical Consumables Procurement Framework Agreement (醫療耗材採購框架協議) entered into by Jiangsu Medical and Handan Renhe Hospital on November 30, 2023
“New Renhe Medicine Procurement Agreement”	the new Medicine Procurement Framework Agreement (藥品採購框架協議) entered into by Qihai Medicine and Handan Renhe Hospital on November 30, 2023
“oncology”	the branch of medicine that deals with cancer
“Original Annual Cap”	the original maximum total amount of fees receivable by Jiangsu Medical from Handan Renhe Hospital under the Existing Renhe Medical Consumables Procurement Agreement for the year ending December 31, 2023
“percentage ratio”	the applicable percentage ratios under Rule 14.07 of the Listing Rules

“Qihai Medicine”	Qihai (Chongqing) Medicine Limited* (棲海(重慶)醫藥有限公司), a limited liability company established in the PRC on August 11, 2021, and a wholly-owned subsidiary of the Company
“Revised Annual Cap”	the revised maximum total amount of fees receivable by Jiangsu Medical from Handan Renhe Hospital under the Existing Renhe Medical Consumables Procurement Agreement for the year ending December 31, 2023 as stated under the section headed “(1) Revision of Annual Cap For the Existing Renhe Medical Consumables Procurement Agreement — Revision of Original Annual Cap” in this announcement
“RMB”	the lawful currency of the PRC
“Share(s)”	ordinary share(s) in the share capital of the Company with nominal value of US\$0.00001 each
“Shareholder(s)”	holder(s) of the Shares
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“Xiangshang Investment”	Shanghai Xiangshang Investment Development Co., Ltd.* (上海向上投資發展有限公司), a limited liability company established in the PRC on September 1, 2015 and owned by Mr. Zhu and Ms. Zhu as to 40% and 60%, respectively
“%”	per cent

By order of the Board  
**Hygeia Healthcare Holdings Co., Limited**  
**Mr. Zhu Yiwen**  
*Chairman*

Hong Kong, November 30, 2023

*As of the date of this announcement, the Board comprises Mr. Zhu Yiwen as chairman and executive Director, Ms. Cheng Huanhuan, Mr. Ren Ai, Mr. Zhang Wenshan and Ms. Jiang Hui as executive Directors, and Mr. Liu Yanqun, Mr. Zhao Chun and Mr. Ye Changqing as independent non-executive Directors.*

\* *For identification purpose only*